FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592342768> ?p ?o ?g. }

• W2592342768 endingPage "38275" @default.
• W2592342768 startingPage "38264" @default.
• W2592342768 abstract "// Harri M. Itkonen 1, * , Michael Brown 2 , Alfonso Urbanucci 1, 14 , Gregory Tredwell 3 , Chung Ho Lau 3 , Stefan Barfeld 1 , Claire Hart 2 , Ingrid J. Guldvik 1 , Mandeep Takhar 4 , Hannelore V. Heemers 7, 8, 9 , Nicholas Erho 4 , Katarzyna Bloch 5 , Elai Davicioni 4 , Rita Derua 6 , Etienne Waelkens 6 , James L. Mohler 10 , Noel Clarke 2, 11, 12 , Johan V. Swinnen 5 , Hector C. Keun 3 , Ole P. Rekvig 13 , Ian G. Mills 1, 14, 15, * 1 Prostate Cancer Research Group, Centre for Molecular Medicine Norway, University of Oslo, Oslo, Norway 2 Genito Urinary Cancer Research Group, Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom 3 Department of Surgery and Cancer, Imperial College London, London, United Kingdom 4 GenomeDx Biosciences, Vancouver, British Columbia, Canada 5 Department of Oncology, Laboratory of Lipid Metabolism and Cancer, LKI Leuven Cancer Institute, KU Leuven-University of Leuven, Leuven, Belgium 6 Department of Cellular and Molecular Medicine, Laboratory of Protein Phosphorylation and Proteomics, KU Leuven-University of Leuven, Leuven, Belgium 7 Department of Cancer Biology, Cleveland Clinic, Cleveland, Ohio, USA 8 Department of Urology, Cleveland Clinic, Cleveland, Ohio, USA 9 Department of Hematology/Medical Oncology, Cleveland Clinic, Cleveland, Ohio, USA 10 Department of Urology, Roswell Park Cancer Institute, Buffalo, New York, USA 11 PCUK/Movember Centre of Excellence for Prostate Cancer Research, CRUK Manchester Institute for Cancer Research, University of Manchester, Manchester, UK 12 Department of Urology, The Christie NHS Foundation Trust, Manchester, UK 13 Department of Medical Biology, University of Tromso, Tromso, Norway 14 Department of Molecular Oncology, Institute for Cancer Research and Oslo University Hospital, Oslo, Norway 15 PCUK/Movember Centre of Excellence for Prostate Cancer Research, Centre for Cancer Research and Cell Biology (CCRCB), Queen's University Belfast, Belfast, UK * Co-corresponding authors Correspondence to: Harri M. Itkonen, email: harri.itkonen@ncmm.uio.no Ian G. Mills, email: ian.mills@ncmm.uio.no Keywords: androgen receptor, lipid degradation, metabolism, ECI2, cell cycle Received: November 17, 2016      Accepted: March 01, 2017      Published: March 11, 2017 ABSTRACT Prostate cancer is the most common male cancer and androgen receptor (AR) is the major driver of the disease. Here we show that Enoyl-CoA delta isomerase 2 (ECI2) is a novel AR-target that promotes prostate cancer cell survival. Increased ECI2 expression predicts mortality in prostate cancer patients ( p = 0.0086). ECI2 encodes for an enzyme involved in lipid metabolism, and we use multiple metabolite profiling platforms and RNA-seq to show that inhibition of ECI2 expression leads to decreased glucose utilization, accumulation of fatty acids and down-regulation of cell cycle related genes. In normal cells, decrease in fatty acid degradation is compensated by increased consumption of glucose, and here we demonstrate that prostate cancer cells are not able to respond to decreased fatty acid degradation. Instead, prostate cancer cells activate incomplete autophagy, which is followed by activation of the cell death response. Finally, we identified a clinically approved compound, perhexiline, which inhibits fatty acid degradation, and replicates the major findings for ECI2 knockdown. This work shows that prostate cancer cells require lipid degradation for survival and identifies a small molecule inhibitor with therapeutic potential." @default.
• W2592342768 created "2017-03-16" @default.
• W2592342768 creator A5009893625 @default.
• W2592342768 creator A5014582211 @default.
• W2592342768 creator A5015814016 @default.
• W2592342768 creator A5017730342 @default.
• W2592342768 creator A5025303265 @default.
• W2592342768 creator A5026531632 @default.
• W2592342768 creator A5028961632 @default.
• W2592342768 creator A5029127354 @default.
• W2592342768 creator A5035786798 @default.
• W2592342768 creator A5042788986 @default.
• W2592342768 creator A5044704274 @default.
• W2592342768 creator A5049996804 @default.
• W2592342768 creator A5061906647 @default.
• W2592342768 creator A5062031834 @default.
• W2592342768 creator A5065195021 @default.
• W2592342768 creator A5069536069 @default.
• W2592342768 creator A5074632643 @default.
• W2592342768 creator A5074919849 @default.
• W2592342768 creator A5082768586 @default.
• W2592342768 creator A5084499108 @default.
• W2592342768 creator A5089777135 @default.
• W2592342768 date "2017-03-11" @default.
• W2592342768 modified "2023-10-16" @default.
• W2592342768 title "Lipid degradation promotes prostate cancer cell survival" @default.
• W2592342768 cites W1558570426 @default.
• W2592342768 cites W1577564589 @default.
• W2592342768 cites W1967557518 @default.
• W2592342768 cites W1968550558 @default.
• W2592342768 cites W1988708470 @default.
• W2592342768 cites W1992532731 @default.
• W2592342768 cites W1992567427 @default.
• W2592342768 cites W1996612168 @default.
• W2592342768 cites W1997730815 @default.
• W2592342768 cites W1998343146 @default.
• W2592342768 cites W1998562191 @default.
• W2592342768 cites W1998691242 @default.
• W2592342768 cites W2001591494 @default.
• W2592342768 cites W2005455243 @default.
• W2592342768 cites W2006022605 @default.
• W2592342768 cites W2014409119 @default.
• W2592342768 cites W2020062992 @default.
• W2592342768 cites W2041237929 @default.
• W2592342768 cites W2043394651 @default.
• W2592342768 cites W2060041328 @default.
• W2592342768 cites W2061467546 @default.
• W2592342768 cites W2062785709 @default.
• W2592342768 cites W2079474262 @default.
• W2592342768 cites W2088516053 @default.
• W2592342768 cites W2091098941 @default.
• W2592342768 cites W2098908969 @default.
• W2592342768 cites W2100305481 @default.
• W2592342768 cites W2102761045 @default.
• W2592342768 cites W2104773254 @default.
• W2592342768 cites W2133465414 @default.
• W2592342768 cites W2134468405 @default.
• W2592342768 cites W2135658869 @default.
• W2592342768 cites W2137467802 @default.
• W2592342768 cites W2137888087 @default.
• W2592342768 cites W2138544728 @default.
• W2592342768 cites W2140116078 @default.
• W2592342768 cites W2158217645 @default.
• W2592342768 cites W2159697997 @default.
• W2592342768 cites W2162508192 @default.
• W2592342768 cites W2168790441 @default.
• W2592342768 cites W2170272782 @default.
• W2592342768 cites W2201259288 @default.
• W2592342768 cites W2257564321 @default.
• W2592342768 cites W2265836483 @default.
• W2592342768 cites W2295060570 @default.
• W2592342768 cites W2334599854 @default.
• W2592342768 cites W4231858634 @default.
• W2592342768 cites W4246681983 @default.
• W2592342768 cites W591639994 @default.
• W2592342768 doi "https://doi.org/10.18632/oncotarget.16123" @default.
• W2592342768 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5503531" @default.
• W2592342768 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28415728" @default.
• W2592342768 hasPublicationYear "2017" @default.
• W2592342768 type Work @default.
• W2592342768 sameAs 2592342768 @default.
• W2592342768 citedByCount "61" @default.
• W2592342768 countsByYear W25923427682017 @default.
• W2592342768 countsByYear W25923427682018 @default.
• W2592342768 countsByYear W25923427682019 @default.
• W2592342768 countsByYear W25923427682020 @default.
• W2592342768 countsByYear W25923427682021 @default.
• W2592342768 countsByYear W25923427682022 @default.
• W2592342768 countsByYear W25923427682023 @default.
• W2592342768 crossrefType "journal-article" @default.
• W2592342768 hasAuthorship W2592342768A5009893625 @default.
• W2592342768 hasAuthorship W2592342768A5014582211 @default.
• W2592342768 hasAuthorship W2592342768A5015814016 @default.
• W2592342768 hasAuthorship W2592342768A5017730342 @default.
• W2592342768 hasAuthorship W2592342768A5025303265 @default.
• W2592342768 hasAuthorship W2592342768A5026531632 @default.
• W2592342768 hasAuthorship W2592342768A5028961632 @default.
• W2592342768 hasAuthorship W2592342768A5029127354 @default.

• next